[In vitro synergism of ulifloxacin plus piperacillin/tazobactam against clinical isolates of Enterobacteriaceae producing extended-spectrum or AmpC-type β-lactamases].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Transliterated Title:
      Sinergismo in vitro tra ulifloxacina e piperacillina/tazobactam verso isolati clinici di enterobatteri produttori di beta-lattamasi a spettro esteso e AmpC.
    • Source:
      Publisher: Edizioni Internazionali srl Country of Publication: Italy NLM ID: 9613961 Publication Model: Print Cited Medium: Internet ISSN: 2532-8689 (Electronic) Linking ISSN: 11249390 NLM ISO Abbreviation: Infez Med Subsets: MEDLINE
    • Publication Information:
      Publication: Pavia, Italy : Edizioni Internazionali srl
      Original Publication: Roma : Elsèv edizioni mediche
    • Subject Terms:
      Anti-Bacterial Agents/*pharmacology ; Bacterial Proteins/*biosynthesis ; Enterobacteriaceae/*drug effects ; Enterobacteriaceae/*enzymology ; Fluoroquinolones/*pharmacology ; Piperazines/*pharmacology ; beta-Lactamases/*biosynthesis; Drug Synergism ; Humans ; Penicillanic Acid/analogs & derivatives ; Penicillanic Acid/pharmacology ; Piperacillin/pharmacology ; Piperacillin, Tazobactam Drug Combination
    • Abstract:
      Extended spectrum beta-lactamase (ESBL) and ampicillinase C (AmpC) producing Enterobacteriaceae are nowadays frequently isolated in clinical practice. Carbapenems are generally the drugs of choice in such a case and resistance to these molecules is on the rise. Rationalizing their use is to be considered essential, possibly identifying alternative regimens. We thus examined 10 strains of Enterobacteriaceae isolated from patients previously unsuccessfully treated with a beta-lactam or a quinolone; eight strains were either ESBL or AmpC producers. Ulifloxacin showed minimum inhibitory concentrations (MICs) lower than ciprofloxacin and levofloxacin. Tested with the checkerboard method, the association of ulifloxacin and piperacillin/tazobactam proved fully synergistic on five strains and partially synergistic on three. The above association was fully synergistic towards three strains resistant to piperacillin/tazobactam and one strain resistant to ulifloxacin, with MICs in association easily obtainable at standard doses. Our in vitro study demonstrates a synergistic activity of ulifloxacin and piperacillin/tazobactam in association towards ESBL and AmpC-producing Enterobacteriaceae. Clinical studies are needed to confirm in vivo the effectiveness of this regimen.
    • Accession Number:
      0 (Anti-Bacterial Agents)
      0 (Bacterial Proteins)
      0 (Fluoroquinolones)
      0 (Piperazines)
      157044-21-8 (Piperacillin, Tazobactam Drug Combination)
      87-53-6 (Penicillanic Acid)
      C38638H76Y (ulifloxacin)
      EC 3.5.2.6 (AmpC beta-lactamases)
      EC 3.5.2.6 (beta-Lactamases)
      X00B0D5O0E (Piperacillin)
    • Publication Date:
      Date Created: 20110104 Date Completed: 20110526 Latest Revision: 20190816
    • Publication Date:
      20231215
    • Accession Number:
      21196818